Semaglutide is a recurring topic in our peptide coverage. This hub collects every article tagged Semaglutide, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-first review of the peptides women are sold for skin, sexual desire, weight, hormones and fertility — graded honestly by human data, with the FDA, WADA and pregnancy cautions marketing leaves out.
The honest, evidence-first ranking of peptides for weight loss — the GLP-1-based incretin agonists that work in human RCTs, and the 'fat-burning' GH-fragment peptides that failed in human trials.
A clinical-evidence ranking of the peptides that actually reduce visceral (belly) fat — one of the rare peptide topics with genuine Grade A human RCT proof — separating the FDA-approved and investigational incretin/GHRH drugs from the gray-market 'fat-loss' peptides that have none.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
An evidence-graded review of the peptide drugs studied for metabolic syndrome — from the Grade A incretin drugs that reverse the whole cluster to the preclinical-only compounds sold online with no completed human trial.
An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
A clinical-evidence ranking of the peptides marketed for insulin sensitivity and blood-sugar control — the incretin drugs that actually work in human RCTs, and the 'mitochondrial' research peptides that do not yet.
A clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
A clinical monograph on CagriSema — Novo Nordisk's investigational once-weekly cagrilintide + semaglutide combination. Grade A Phase 3 RCT data, ~20-23% weight loss, and a 2026 legal status that is still investigational worldwide.
Semaglutide is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Semaglutide, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.